A carregar...

Targeting the MAPK Pathway in RAS Mutant Cancers

Despite decades of extensive drug discovery efforts, there are currently no targeted therapies approved to treat KRAS mutant cancers. In this review, we highlight the challenges and opportunities in targeting KRAS mutant tumors through inhibition of mitogen-activated protein kinase (MAPK) signaling...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cold Spring Harb Perspect Med
Main Authors: Hymowitz, Sarah G., Malek, Shiva
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory Press 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6211377/
https://ncbi.nlm.nih.gov/pubmed/29440321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/cshperspect.a031492
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!